Brunelli SM, Gagne JJ, Huybrechts KF, Wang SV, Patrick AR, Rothman KJ, Seeger JD. Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. Pharmacoepidemiol Drug Saf. 2013 Mar 22;Advance Online.
Kilpatrick RD, Gilbertson D, Brookhart MA, Polley E, Rothman KJ, Bradbury BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions. Pharmacoepidemiol Drug Saf. 2013 Feb 1;22(2):111-21.
Thyagarajan (Hoffman) V, Robin Clifford C, Wurst KE, Ephross SA, Seeger JD. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1240-2. doi: 10.1002/pds.3271
Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012 Aug 1;21(8):810-7.
Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Response to commentary by Marcus and Gibbons. Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):713.
Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012 Jul 1;21(7):697-709.
Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, Lewis J, Mines D, Barrett JS, Bilker W, Strom BL. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012 May;21(5):494-506. doi: 10.1002/pds.3199
Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012 May 1;21(Suppl. 2):69-80.
Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. Optimal approaches to one-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(Supp 3):S34-5.
Sturkenboom M, Fourrier-Reglat A, Perez-Gutthann S, Garbe E, Nicotra F, Romio S. How to conduct collaborative studies in the EU? Lessons and results from the completed Safety of NSAIDs (SOS) Project. Pharmacoepidemiol Drug Saf. 2012;21(suppl 3):S38-9.
Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenboom M, Perez-Gutthann S. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011 Dec 1;20(12):1225-36.
Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ. The association of vitamin d use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case–crossover study. Pharmacoepidemiol Drug Saf. 2011 Sep 1;20(9):914-21.
Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, Avorn J, Sturmer T. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf. 2011 Jun 1;20(6):551-9.
Mines D, Gu Y, Kou TD, Cooper GS. Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):111-8. doi: 10.1002/pds.2057
Johannes CB, Varas-Lorenzo C, McQuay L, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010 Sep 1;19(9):881-8.
Mines D. Invited editorial. Commentary on the validation studies of sudden cardiac death and ventricular arrhythmia by Hennessy et al. and Chung et al. Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):573-5. doi: 10.1002/pds.1913.
Varas-Lorenzo C, Castellsaque J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1016-25.
Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall-Vila M, Williams LK. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722
Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cycoxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18(11):1016-25.
Rothman KJ, Suissa S. Exclusion of immortal person-time. Pharmacoepidemiol Drug Saf. 2008 Oct 1;17(10):1036.
Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Arana A, Rothman KJ. Use of Cyclo-Oxygenase 2 Inhibitors (COX-2) and prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in UK and USA populations. Pharmacoepidemiol Drug Saf. 2008 Oct 1;17(10):1037. doi: 10.1002/pds.1636
Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf. 2008 Aug 1;17(8):842-52.
Varas-Lorenzo C, Castellsaque J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of icd-9 codes 410-411 for acute coronary syndromes: saskatchewan hospital automated database. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):842-52.
Gutierrez LP, Koltowska-Haggstrom M, Jonsson PJ, Mattsson AF, Svensson D, Westberg B, Luger A. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf. 2008 Jan 1;17(1):90-102.
Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, Jick H, Johnson CC. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf. 2007 Oct 1;16(9):961-8.
Johannes CB, Seeger JD, Koro CE, Cutone JA, Quinn SG. Response to a comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'. Pharmacoepidemiol Drug Saf. 2007 Oct 1;16(10):1073-4.
Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf. 2007 May 1;16(5):504-12.
Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiol Drug Saf. 2007 Apr 1;16(4):366-76.
Perez-Gutthann S, Cook S, Dai W, Hirst C, Andrews E. A call for international harmonization in therapeutic risk management. Pharmacoepidemiol Drug Saf. 2006 Dec 1;15(12):839-49.
Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Use of Cyclo-Oxygenase 2 Inhibitors (COX-2) and prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf. 2006 Dec 1;15(12):861-72.
Gonzalez-Perez A, Fernandez-Vidaurre C, Rueda A, Rivero E, Garcia-Rodriguez LA. Cancer incidence in a general population of asthma patients. Pharmacoepidemiol Drug Saf. 2006 Nov 15;15(2):131-8.
Sturmer T, Rothman KJ, Glynn RJ. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf. 2006 Oct 1;15(10):698-709.
Arellano FA, Wentworth CE, May C, Verma A, Rivero E, Rothman KJ. Use of prescription cyclo-oxigenase 2 inhibitors (COX-2) and non cox-2 non-steroidal anti-inflammatory drugs (NSAIDS) in a UK population. Pharmacoepidemiol Drug Saf. 2005 Jul;14(Suppl 1):S141.
Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):367-72.
Rothman KJ, Lanes S, Sacks ST. Measuring drug effects means getting a clearer signal. Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):527-8.
Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(8):519-23.
Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(5):295-8.
Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(4):227-37.
Maguire A, Melero-Montes M, Saez-Lloret I, Varas-Lorenzo C, Perez-Gutthann S. Changes in hypokalemia and hyperkalemia prevalence between 1991 and 2000 in the US according to hypertensive status and treatment. Pharmacoepidemiol Drug Saf. 2004;13:S303.
Rothman KJ, Ray W. Should cases with a 'known' cause of their disease be excluded from study? (Commentary). Pharmacoepidemiol Drug Saf. 2002 Jan 1;11(1):11-4.
Rothman KJ, Ray W. Should epidemiologists exclude cases with a known cause of their disease? Pharmacoepidemiol Drug Saf. 2002;11:11-4.
Rothman KJ, Lanza L, Lal A, Peskin EG, Dreyer NA. Incidence of pelvic inflammatory disease among women treated for gonorrhea and chlamydia. Pharmacoepidemiol Drug Saf. 1996 Nov 5;5(6):409-14.